Clinical Trial Update: An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease [Phase 3]

View source ↗

Summary

Pfizer conducted an extension of the Phase 3 B1451006 protocol to evaluate the safety and efficacy of Dimebon (latrepirdine) in moderate-to-severe Alzheimer's d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Dimebon (latrepirdine)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2012-10-02